![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Pease James E Horuk Richard
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.14, Iss.7, 2005-07, pp. : 785-796
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Current Topics in Medicinal Chemistry, Vol. 14, Iss. 13, 2014-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
CCR1 Antagonists: What Have We Learned From Clinical Trials
Current Topics in Medicinal Chemistry, Vol. 10, Iss. 13, 2010-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Novel chemokine CCR1 receptor antagonists
Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 8, 2001-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
1-Acyl-4-benzyl-2,5-transdimethyl-piperazine CCR1 antagonists
By Norman Peter
Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 3, 2006-03 ,pp. :